Wall Street Analysts Think Anavex Life Sciences (AVXL) Could Surge 338.45%: Read This Before Placing a BetZacks Investment Research • 05/31/23
Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 342.31%: Here's is How to TradeZacks Investment Research • 05/15/23
Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Results on Tuesday, May 9, 2023GlobeNewsWire • 05/02/23
Anavex Life Sciences Announces Issuance of New U.S. Patent Expanding ANAVEX®2-73 (blarcamesine) Intellectual Property Portfolio for the Treatment of HypertensionGlobeNewsWire • 05/01/23
Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQGlobeNewsWire • 04/25/23
Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023GlobeNewsWire • 04/10/23
ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson's Disease DementiaGlobeNewsWire • 03/30/23
Anavex: Many Questions Answered, A Few Still Left, But Things Are Progressing WellSeeking Alpha • 03/08/23
Does Anavex Life Sciences (AVXL) Have the Potential to Rally 270.28% as Wall Street Analysts Expect?Zacks Investment Research • 02/15/23
Anavex Life Sciences: Recent Earnings Reveals Strong Cash Position To Get ANAVEX 2-73 Through FDASeeking Alpha • 02/09/23
Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical TrialGlobeNewsWire • 02/02/23
Approval For Anavex's Blarcamesine Looks Inevitable After Biogen's Leqembi ApprovedSeeking Alpha • 01/30/23